Prograf-XL
Drugoral
Other names: tacrolimus extended release, FK506E, MR4
NCT Number: NCT00720408
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF and steroid withdrawal in de novo Liver transplant recipients
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 3
Kaohsiung City, Taiwan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
oral
Other names: tacrolimus extended release, FK506E, MR4
oral
Other names: tacrolimus, FK506
oral
Other names: Mycophenolate Mofetil
Time frame: 6 month
Time frame: 6 and 12 month
Time frame: 12 month
Time frame: 6 and 12 month
Astellas Pharma Inc
Industry
A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF and Extended Release (XL) Tacrolimus /MMF and Steroid Withdraw in de Novo Liver Transplant Recipients.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07728604
Behavior, Health Behavior
Izmir, Turkey (Türkiye)
View Trial DetailsNCT01294020
Heart Transplantation, Intestine Transplantation
Brussels, Belgium
View Trial DetailsNCT07233083
Liver Transplantation, Neurologic Manifestations
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07233096
Liver Transplantation, Living Donor
Istanbul, Turkey (Türkiye)
View Trial Details